Covigenix VAX 001
Alternative Names: COVID-19 DNA vaccine - Entos Pharmaceuticals; COVID-2019 DNA vaccine - Entos Pharmaceuticals; Covigenix VAX-001; SARS-COV-2 vaccine - Entos PharmaceuticalsLatest Information Update: 01 Mar 2024
At a glance
- Originator Entos Pharmaceuticals
- Class COVID-19 vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 06 Dec 2023 Entos Pharmaceuticals completes a phase-I/II trial in COVID-2019 infections (Prevention) in Burkina Faso, Canada, Senegal and South Africa (IM) (NCT04591184)
- 30 Sep 2022 Entos Pharmaceuticals completes enrollment in its phase-II clinical trial in COVID-2019 infections (Prevention, In adults, In the elderly) in Burkina Faso (IM) (NCT04591184)
- 02 Sep 2021 Entos Pharmaceuticals receives approval from the South African Health Products Regulatory Authority (SAHPRA) to initiate a phase II clinical trial of covigenix VAX 001 in COVID-2019 infections